Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin

Arch Biochem Biophys. 1999 Oct 1;370(1):112-8. doi: 10.1006/abbi.1999.1371.

Abstract

Human tissue factor pathway inhibitor-2 (TFPI-2)/matrix-associated serine protease inhibitor (MSPI), a Kunitz-type serine protease inhibitor, inhibits plasmin, trypsin, chymotrypsin, plasma kallikrein, cathepsin G, and factor VIIa-tissue factor complex. The mature protein has a molecular mass of 32-33 kDa, but exists in vivo as two smaller, underglycosylated species of 31 and 27 kDa. TFPI-2/MSPI triplet is synthesized and secreted by a variety of cell types that include epithelial, endothelial, and mesenchymal cells. Because the majority (75-90%) of TFPI-2/MSPI is associated with the extracellular matrix (ECM), we examined which components of the ECM bind TFPI-2/MSPI. We found that TFPI-2/MSPI bound specifically to heparin and dermatan sulfate. Interaction of these two glycosaminoglycans (GAGs) with TFPI-2/MSPI involved one or more common protein domains, as evidenced by cross-competition experiments. However, binding affinity for TFPI-2/MSPI with heparin was 250-300 times greater than that for TFPI-2/MSPI with dermatan sulfate. Binding of TFPI-2/MSPI to GAGs was inhibited by NaCl or arginine but not by glucose, mannose, galactose, 6-aminohexanoic acid, or urea, suggesting that arginine-mediated ionic interactions participate in the GAG binding of TFPI-2/MSPI. This supposition was supported by the observation that only NaCl or arginine could elute the TFPI-2/MSPI protein triplet from an ECM derived from human dermal fibroblasts. Reduced TFPI-2/MSPI did not bind to heparin, suggesting that proper disulfide pairings and conformation are essential for matrix binding. To determine whether heparin modulates the activity of TFPI-2/MSPI, we determined the rate of inhibition of plasmin by the inhibitor with and without heparin and found that TFPI-2/MSPI is more active in the presence of heparin. Collectively, our results demonstrate that conformation-dependent arginine-mediated ionic interactions are responsible for the TFPI-2/MSPI triplet binding to fibroblast ECM, heparin, and dermatan sulfate and that heparin augmented the rate of inhibition of plasmin by TFPI-2/MSPI.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arginine / metabolism*
  • Binding, Competitive
  • Cathepsin G
  • Cathepsins / antagonists & inhibitors
  • Chymotrypsin / metabolism
  • Cysteine Endopeptidases / metabolism
  • Dermatan Sulfate / metabolism*
  • Dermatan Sulfate / pharmacology
  • Fibrinolysin / antagonists & inhibitors*
  • Glycoproteins / metabolism
  • Glycoproteins / pharmacology*
  • Heparin / metabolism*
  • Heparin / pharmacology
  • Humans
  • Kallikreins / antagonists & inhibitors
  • Kinetics
  • Neoplasm Proteins*
  • Pregnancy Proteins / metabolism
  • Pregnancy Proteins / pharmacology*
  • Serine Endopeptidases
  • Serine Proteinase Inhibitors / pharmacology*
  • Trypsin / metabolism

Substances

  • Glycoproteins
  • Neoplasm Proteins
  • Pregnancy Proteins
  • Serine Proteinase Inhibitors
  • tissue-factor-pathway inhibitor 2
  • Dermatan Sulfate
  • Heparin
  • Arginine
  • Cathepsins
  • Kallikreins
  • Serine Endopeptidases
  • Chymotrypsin
  • CTSG protein, human
  • Cathepsin G
  • Trypsin
  • Fibrinolysin
  • Cysteine Endopeptidases
  • cancer procoagulant